Prism Pharma Co., Ltd.

Prism Biolab Co., Ltd.

Asahi Kasei Kogyo Kabushiki Kaisha

Prism Biolab Corporation

Eisai R&d Management Co., Ltd.

Hiroyuki Kouji

Takenao Odagami

Yuji Kogami

Michinori Kohara

Teruyuki Misumi

Yoichi Ozawa

Yusaku Hori

Yoshiharu Hayashi

Takanao Odagami

The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.

Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

CBP/&#x3b2;-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis.

Prevention or treatment agent for hepatic fibrosis

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Alpha helix mimetics and methods relating thereto

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed. 

An N-substituted-phenylteraconimide compound represented by the formula ##STR1## wherein X and R are as defined in the disclosure, herbicidal composition and method for the destruction of undesirable weeds. The herbicides comprising the above compounds are capable of selectively controlling undesirable weeds among desirable crop plants.

N-substituted-phenylteraconimide compound, herbicidal composition, and

Phenylacetic esters, thioesters and amides of the formula ##STR1## wherein R is as defined in the disclosure, process for preparation thereof, herbicidal composition and method for destruction of undesirable weeds. The herbicides comprising the above compounds are capable of selectively controlling undesirable weeds among desirable crop plants.

Growing community of inventors

Yokohama, Japan

Hiroyuki Kouji